Meningococcal Vaccine Market

Report Highlights

The report focused on the different types and brands of Meningococcal Vaccines. The report also focused on the affected age group by meningococcal infection. Furthermore, the scope of the report also covers the impact of COVID-19 and drivers and challenges for Meningococcal Vaccine market. The report covers the market value for the historic year 2019, followed by the base year 2020, estimated year 2021 and forecast period from 2020 to 2026 for each type, brand, age group, end-user and regional markets, and the estimated values are derived from the manufacturers’ total revenues.

The report also includes a discussion of the major players across each of the regional Meningococcal Vaccine markets; it explains the major market drivers of the Global Meningococcal Vaccine industry, current trends within the industry, major applications, and the regional dynamics of the Global Meningococcal Vaccine Market.

The report concludes with a special focus on the vendor landscape, which includes detailed profiles of the major vendors in the Global Meningococcal Vaccine Market.

Report Includes

• 41 tables and 49 figures
• An up-to-date analysis of the Global Meningococcal Vaccine Market.
• Analyses of the global market trends, with data from 2019, 2020, estimates for 2021, and projections of compound annual growth rates (CAGRs) through 2026.
• Estimation of market size and revenue forecast for Global Meningococcal Vaccine Market, and corresponding market share analysis by type, brand, age group, end-user, and region.
• Highlights of emerging technology trends, gaps and opportunities in the market estimating current and future demand for Meningococcal Vaccine, identification of the companies that are best positioned to meet this demand.
• In-depth information (facts and figures) concerning market drivers, restraints and other forces affecting the progress of this market.
• Identification of promising new vaccines, and products still in the development and testing stages, and their probability of successful commercial launch within the next five years
• Impact of COVID-19 on the Meningococcal Vaccine Market as compared to overall global economy.
• Insight into the growth development strategies of major Meningococcal Vaccine manufacturers and their key competitive landscape
• Descriptive company profiles of the leading market participants, including Pfizer Inc., Sanofi S.A., Serum Institute of India Pvt. Ltd., GlaxoSmithKline plc, Merck & Co., Inc., Novartis International AG and others.

Summary

Meningococcal meningitis often referred to as, neisseria meningitidis is one a rare disease caused by severe bacterial infection. In this disease, the bacteria act upon the lining of spinal cord and brain which can cause severe damage as well as endemics. The transmission of the disease is possible either coming in direct contact with the infected person or by directly contacting respiratory or throat secretions of the infected person. According to the Centers for Disease Control and Prevention (CDC), every year around 1.2 million cases are registered for bacterial meningitis globally. The disease is highly fatal and can cause severe complications if the disease is left untreated. Meningococcal vaccines are used to prevent the meningococcal bacterial infection. Some of the common factors driving the global meningococcal vaccine market are increasing awareness among the population by setting up more awareness programs and production of cost-effective vaccines which are easily afforded by the patients. There are mainly two types of meningococcal vaccines which are widely used globally namely, bivalent and quadrivalent meningococcal vaccines.